FDA Endorses New Pain Pill
This is a news story, published by Global News, that relates primarily to Journavx news.
Journavx news
For more Journavx news, you can click here:
more Journavx newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsGlobal News news
For more news from Global News, you can click here:
more news from Global NewsAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
opioid painkillers. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest opioid medicines news, pain pill news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Vertex PharmaceuticalsGlobal News
•Health
Health
New pain pill approved in U.S. designed to cut risk of addiction - National | Globalnews.ca

74% Informative
Vertex Pharmaceuticals' Journavx is the first new pharmaceutical approach to treating pain in more than 20 years .
The new drug will carry a list price of $ 15.50 per pill, making it many times more expensive than comparable opioids.
The drug works differently, blocking proteins that trigger pain signals later sent to the brain.
VR Score
81
Informative language
85
Neutral language
55
Article tone
semi-formal
Language
English
Language complexity
63
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links